Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.68M Sell
24,951
-3,769
-13% -$251K 0.01% 614
2026
Q1
$1.8M Buy
28,720
+615
+2% +$42.8K 0.01% 553
2025
Q4
$1.87M Sell
28,105
-56,862
-67% -$3.68M 0.01% 550
2025
Q3
$5.72M Buy
84,967
+15,024
+21% +$1.19M 0.03% 318
2025
Q2
$6.11M Buy
69,943
+24,807
+55% +$1.94M 0.03% 292
2025
Q1
$3.08M Buy
45,136
+6,615
+17% +$540K 0.02% 395
2024
Q4
$3M Buy
38,521
+873
+2% +$64.6K 0.02% 388
2024
Q3
$2.52M Buy
37,648
+30,370
+417% +$2.49M 0.01% 426
2024
Q2
$825K Buy
7,278
+274
+4% +$34.6K 0.01% 666
2024
Q1
$971K Buy
7,004
+598
+9% +$75.2K 0.01% 627
2023
Q4
$795K Sell
6,406
-588
-8% -$60.1K 0.01% 643
2023
Q3
$653K Sell
6,994
-96
-1% -$10.8K ﹤0.01% 655
2023
Q2
$911K Buy
7,090
+679
+11% +$82.1K 0.01% 585
2023
Q1
$745K Sell
6,411
-9,840
-61% -$1.1M 0.01% 611
2022
Q4
$1.84M Sell
16,251
-105
-0.6% -$11.5K 0.02% 381
2022
Q3
$1.32M Buy
16,356
+3,573
+28% +$303K 0.01% 429
2022
Q2
$953K Buy
12,783
+7,107
+125% +$649K 0.01% 517
2022
Q1
$726K Buy
5,676
+144
+3% +$15.8K 0.01% 628
2021
Q4
$743K Buy
5,532
+104
+2% +$14.9K ﹤0.01% 654
2021
Q3
$742K Buy
5,428
+920
+20% +$116K 0.01% 612
2021
Q2
$481K Buy
4,508
+2,248
+99% +$216K ﹤0.01% 656
2021
Q1
$203K Sell
2,260
-44
-2% -$4.13K ﹤0.01% 757
2020
Q4
$213K Buy
2,304
+184
+9% +$16.4K ﹤0.01% 732
2020
Q3
$218K Buy
2,120
+20
+1% +$2.09K ﹤0.01% 658
2020
Q2
$213K Buy
+2,100
New +$188K ﹤0.01% 625

Other funds holding DXCM

Davenport & Co's DXCM Position: Q2 2026 in Review

Davenport & Co reduced its DexCom (DXCM) stake by 13% in Q2 2026, selling an estimated $251K and leaving 24,951 shares worth $1.68M. The position accounts for 0.01% of the portfolio, ranked #614.

Davenport & Co first reported a position in DXCM in Q2 2020 and has held it in 25 quarters since. The position peaked at $6.11M in Q2 2025. 151 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Davenport & Co held 24,951 shares of DexCom worth $1.68M as of Q2 2026.
  • Davenport & Co sold 3,769 DexCom shares in Q2 2026, an estimated $251K.
  • DexCom made up 0.01% of Davenport & Co's portfolio in Q2 2026, its #614 holding.
  • Davenport & Co first reported a position in DexCom in Q2 2020 and has held it in 25 quarters since.
  • Davenport & Co's DexCom position peaked at $6.11M in Q2 2025.
  • 151 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.